Sugemalimab
Sugemalimab Uses, Dosage, Side Effects, Food Interaction and all others data.
Sugemalimab is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody discovered by CStone Pharmaceuticals and being investigated against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) in adult patients and T-cell lymphoma. It has been granted the Breakthrough Therapy Designation by the FDA to treat R/R ENKTL and orphan drug designation to treat T-cell lymphoma.
During studies, sugemalimab was well tolerated and has shown antitumor activity in multiple tumor types. Sugemalimab is under investigation in clinical trial NCT03802591 (A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-esophageal Junction Adenocarcinoma).
| Trade Name | Sugemalimab |
| Generic | Sugemalimab |
| Sugemalimab Other Names | CS 1001, Sugemalimab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
How Sugemalimab works
Sugemalimab, a monoclonal antibody, targets the programmed death-ligand 1 (PD-L1).
Innovators Monograph
You find simplified version here Sugemalimab
